<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638651</url>
  </required_header>
  <id_info>
    <org_study_id>20071234</org_study_id>
    <nct_id>NCT00638651</nct_id>
  </id_info>
  <brief_title>Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal</brief_title>
  <official_title>Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of tattoo removal using topical
      imiquimod, 5% cream in conjunction with the 1064nm Nd:YAG laser. This procedure for tattoo
      removal will be compared to a laser removal alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria includes: patients of both genders with Fitzpatrick skin types I-IV who
      are 18-65 years of age and who has 2 tattoos from 2 to 10 cm in diameter, of similar age
      which contains black and/or blue ink in areas that can be covered. Exclusion criteria
      includes: tattoos in chronically sun exposed areas, larger than 25 cm2,pregnancy,breast
      feeding state, immunosuppressed patients, history of autoimmune or connective tissue
      disorders, hypersensitivity to imiquimod, active sunburn, current tan, use of coumadin,
      aspirin , vitamin E or non-steroidal anti-inflammatory agents for the past 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream</measure>
    <time_frame>approximately 14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream (Aldaraâ„¢, 3M/Graceway Pharmaceuticals, an immune response modifier) in conjunction with the 1064 nm Nd:YAG laser. This procedure for tattoo removal will be compared to laser removal alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleaching of the Tattoo</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The tattoo will be treated with laser and imiquimod 5% cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The tattoo will be treated with laser and placebo topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1064 nm Nd:YAG laser</intervention_name>
    <description>The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod, 5% cream</intervention_name>
    <description>2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 tattoos no larger than 25cm2, professionally made, with approximately the same age,
             containing blue/black ink.

        Exclusion Criteria:

          -  Hypersensitivity to imiquimod

          -  Current sun tan

          -  Use of vitamin E, non-steroid anti-inflammatory drugs, coumadin or aspirin for the
             past 10 days

          -  Amateur tattoos

          -  Pregnancy

          -  Breast-feeding status

          -  Immunosuppression

          -  Auto-immune diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyvan Nouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mohs, Dermatologic and Laser Surgery</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Elsaie ML, Nouri K, Vejjabhinanta V, Rivas MP, Villafradez-Diaz LM, Martins A, Rosso R. Topical imiquimod in conjunction with Nd:YAG laser for tattoo removal. Lasers Med Sci. 2009 Nov;24(6):871-5. doi: 10.1007/s10103-009-0709-9. Epub 2009 Jul 15.</citation>
    <PMID>19597914</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 20, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2008</firstreceived_date>
  <firstreceived_results_date>August 20, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Keyvan Nouri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Tattoos</keyword>
  <keyword>Black/blue tattoos</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laser Treatment With Imiquimod Cream (Group 1)</title>
          <description>The tattoo will be treated with laser and imiquimod 5% cream</description>
        </group>
        <group group_id="P2">
          <title>Laser Treatment With Placebo Cream (Group 2)</title>
          <description>The tattoo will be treated with laser and placebo topical cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laser Treatment With Imiquimod Cream (Group 1)</title>
          <description>The tattoo will be treated with laser and imiquimod 5% cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Imiquimod, 5% cream: 2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month</description>
        </group>
        <group group_id="B2">
          <title>Laser Treatment With Placebo Cream (Group 2)</title>
          <description>The tattoo will be treated with laser and placebo topical cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream</title>
        <description>To evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream (Aldaraâ„¢, 3M/Graceway Pharmaceuticals, an immune response modifier) in conjunction with the 1064 nm Nd:YAG laser. This procedure for tattoo removal will be compared to laser removal alone.</description>
        <time_frame>approximately 14 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment With Imiquimod (Group 1)</title>
            <description>The tattoo will be treated with laser and imiquimod 5% cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Imiquimod, 5% cream: 2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month</description>
          </group>
          <group group_id="O2">
            <title>Laser Treatment With Placebo Cream (Group 2)</title>
            <description>The tattoo will be treated with laser and placebo topical cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream</title>
            <description>To evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream (Aldaraâ„¢, 3M/Graceway Pharmaceuticals, an immune response modifier) in conjunction with the 1064 nm Nd:YAG laser. This procedure for tattoo removal will be compared to laser removal alone.</description>
            <units>percentage of tattoo pigment removed</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" lower_limit="0" upper_limit="5"/>
                  <measurement group_id="O2" value="2.7" lower_limit="0" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleaching of the Tattoo</title>
        <time_frame>14 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Laser Treatment With Imiquimod Cream (Group 1)</title>
          <description>The tattoo will be treated with laser and imiquimod 5% cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
Imiquimod, 5% cream: 2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month</description>
        </group>
        <group group_id="E2">
          <title>Laser Treatment With Placebo Cream (Group 2)</title>
          <description>The tattoo will be treated with laser and placebo topical cream
1064 nm Nd:YAG laser: The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Keyvan Nouri</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-243-3380</phone>
      <email>knouri@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
